Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- HUMAN GENE THERAPY29(3) · pp.299 · 2018
- 피인용
- Web of Science 63Scopus 67
- FWCI (Scopus)
- 1.95
- JCR IF
- JCR 2017 4.241
- ISSN
- 1043-0342
저자
- Kodippili, Kasun제1저자Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- Hakim, Chady H.Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- Pan, XiufangDepartment of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- Yang, Hsiao T.Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- Yue, YongpingDepartment of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- Zhang, YadongDepartment of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- 신진홍Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
- Yang, N. NoraNational Center for Advancing Translational Sciences, Bethesda, United States
- Duan, Dongsheng교신저자Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, United States
초록
Dual adeno-associated virus (AAV) technology was developed in 2000 to double the packaging capacity of the AAV vector. The proof of principle has been demonstrated in various mouse models. Yet, pivotal evidence is lacking in large animal models of human diseases. Here we report expression of a 7-kb canine H2-R15 mini-dystrophin gene using a pair of dual AAV vectors in the canine model of Duchenne muscular dystrophy (DMD). The H2-R15 minigene is by far the most potent synthetic dystrophin gene engineered for DMD gene therapy. We packaged minigene dual vectors in Y731F tyrosine-modified AAV-9 and delivered to the extensor carpi ulnaris muscle of a 12-month-old affected dog at the dose of 2x10(13) viral genome particles/vector/muscle. Widespread mini-dystrophin expression was observed 2 months after gene transfer. The missing dystrophin-associated glycoprotein complex was restored. Treatment also reduced muscle degeneration and fibrosis and improved myofiber size distribution. Importantly, dual AAV therapy greatly protected the muscle from eccentric contraction-induced force loss. Our data provide the first clear evidence that dual AAV therapy can be translated to a diseased large mammal. Further development of dual AAV technology may lead to effective therapies for DMD and many other diseases in human patients.
키워드
dystrophinDuchenne muscular dystrophycanine modeladeno-associated virusdual AAV vectorsmini-dystrophinADENOASSOCIATED VIRAL VECTORSPACKAGING CAPACITYBETA-DYSTROGLYCANACTIN-BINDINGANIMAL-MODELSDMD GENEMDX MICEEXPRESSIONMUSCLEVIRUS
식별자
- Scopus EID
- 2-s2.0-85043535458
- WoS UID
- 000429742300003



로그인
연구물 목록으로